This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway
Journal of Translational Medicine Open Access 12 August 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Ho, P. et al. The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity. Preprint at bioRxiv https://doi.org/10.1101/2022.03.21.485049 (2022)
Related article
Quastel, M. Preprint Journal Club. PreprintClub https://www.preprintclub.com/2022-apr-ho (2022)
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Quastel, M., Dustin, M. The CD58–CD2 axis in cancer immune evasion. Nat Rev Immunol 22, 409 (2022). https://doi.org/10.1038/s41577-022-00738-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-022-00738-9
This article is cited by
-
CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway
Journal of Translational Medicine (2023)